ArticleAsian Pacific journal of cancer prevention : APJCP2025
Mismatch Repair Gene Deficiency in Ovarian Cancer: A Clinicopathological Analysis of MLH1, PMS2, MSH2, and MSH6 Mutations Across Histological Subtypes.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimMismatch repair (MMR) deficiency is a prognostic biomarker in multiple malignancies, but its clinical significance in ovarian cancer (OC) remains poorly defined. This study investigates the prevalence of MMR gene defects (MLH1, PMS2, MSH2, MSH6) across OC histotypes and their clinicopathological associations.
methodsA retrospective cohort of 38 OC patients treated at Azerbaijan Medical University (2018-2023) underwent immunohistochemical (IHC) analysis of MMR protein expression. Clinicopathological data, including survival, recurrence, tumor characteristics, and biomarker status (Ki67, p53), were analyzed using SPSS v26.0. MMR deficiency was defined as loss of nuclear expression in ≥1 protein.
resultsMMR deficiency was identified in 5.2% of cases (2/38), restricted to endometrioid carcinomas (33.3% of endometrioid cases, 2/6). No deficiencies occurred in serous (n=27), clear cell (n=2), or mixed subtypes (n=3). Endometrioid tumors exhibited larger mean tumor size (13.7 ±5.2 cm vs. 10.0 ±3.7 cm in serous; p=0.01) and distinct Ki67/p53 expression patterns (p<0.05). Despite 55.3% overall mortality (21/38), MMR-deficient cases showed no recurrence or mortality. Serous carcinomas had the highest recurrence (37.0%, 10/27) and mortality rates (70.4%, 19/27). Five-year survival was 81.6%, with no significant association between MMR status and survival (p>0.05).
conclusionMMR deficiency in OC is histotype-dependent, occurring exclusively in endometrioid carcinomas. While not prognostic in this cohort, dMMR screening may guide surveillance for synchronous malignancies and identify candidates for immunotherapy. Multicenter studies with expanded cohorts are needed to validate clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.